MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jaad.2016.09.006

Медицинская библиотека · Journal of the American Academy of Dermatology · 2016

Tofacitinib for the treatment of alopecia areata and variants in adolescents.

Craiglow Brittany G, Liu Lucy Y, King Brett A

СтатьяПеревод в очереди

Аннотация

BACKGROUND

There are no reliably effective therapies for alopecia areata (AA).

OBJECTIVE

We sought to evaluate the benefit and adverse effects of the Janus kinase 1/3 inhibitor, tofacitinib, in a series of adolescent patients with AA.

METHODS

We reviewed the records of 13 adolescent patients with AA treated with tofacitinib. Severity of disease was assessed using the Severity of Alopecia Tool (SALT). Adverse events were evaluated by laboratory monitoring, physical examinations, and review of systems.

RESULTS

Thirteen patients, aged 12 to 17 years, with AA were treated with tofacitinib. Nine patients experienced clinically significant hair regrowth. Median percent change in SALT score was 93% (mean 61%; 1%-100%) at an average of 6.5 months of treatment. Adverse events were mild.

LIMITATIONS: Limitations include the retrospective nature of the data, small sample size, and lack of a control group.

CONCLUSION

Tofacitinib is a promising therapy for AA in adolescents. The use of tofacitinib and other Janus kinase inhibitors for the treatment of AA in this age group should be further evaluated in prospective clinical trials.

Для цитирования: Craiglow Brittany G, Liu Lucy Y, King Brett A. Tofacitinib for the treatment of alopecia areata and variants in adolescents.. Journal of the American Academy of Dermatology. 2016. DOI: 10.1016/j.jaad.2016.09.006.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.